Rapport Therapeutics (RAPP) CDO sells 19,865 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares of common stock in open-market transactions. The sales occurred on April 10, 13, and 14, 2026 at weighted average prices of $34.98, $34.97, and $35.08 per share, respectively. According to the filing, these trades were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following the last sale, he continues to directly own 266,651 shares of Rapport Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 19,865 shares ($695,823)

Net Sell 3 txns

Insider Yeleswaram Krishnaswamy

Role Chief Development Officer

Sold 19,865 shs ($696K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,200	$35.0781	$358K
Sale	Common Stock	9,165	$34.974	$321K
Sale	Common Stock	500	$34.98	$17K

Holdings After Transaction: Common Stock — 266,651 shares (Direct)

Footnotes (1)

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Total shares sold: 19,865 shares Sale on April 14, 2026: 10,200 shares at $35.0781/share Sale on April 13, 2026: 9,165 shares at $34.9740/share +2 more

5 metrics

Total shares sold 19,865 shares Open-market sales of Rapport Therapeutics common stock

Sale on April 14, 2026 10,200 shares at $35.0781/share Open-market sale of common stock

Sale on April 13, 2026 9,165 shares at $34.9740/share Open-market sale of common stock

Sale on April 10, 2026 500 shares at $34.9800/share Open-market sale of common stock

Shares owned after last sale 266,651 shares Direct ownership of Rapport Therapeutics common stock

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/14/2026 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last)

(First)

(Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/10/2026		S⁽¹⁾		500	D	$34.98	286,016	D
Common Stock	04/13/2026		S⁽¹⁾		9,165	D	$34.974⁽²⁾	276,851	D
Common Stock	04/14/2026		S⁽¹⁾		10,200	D	$35.0781⁽³⁾	266,651	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock activity did Rapport Therapeutics (RAPP) report for Yeleswaram Krishnaswamy?

Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares of common stock in three open-market transactions. These trades took place on April 10, 13, and 14, 2026, at weighted average prices around $35 per share, under a pre-arranged 10b5-1 plan.

How many Rapport Therapeutics (RAPP) shares does the CDO still hold after these Form 4 sales?

After the reported sales, Chief Development Officer Yeleswaram Krishnaswamy directly holds 266,651 shares of Rapport Therapeutics common stock. This figure reflects his position following the final sale on April 14, 2026, and helps show that he retains a substantial equity stake in the company.

At what prices were the Rapport Therapeutics (RAPP) shares sold in this Form 4 filing?

The filing lists weighted average sale prices of $34.98 per share on April 10, $34.97 per share on April 13, and $35.08 per share on April 14, 2026. Footnotes explain that each day’s sales occurred in multiple trades within narrow price ranges.

Was the Rapport Therapeutics (RAPP) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades in advance, indicating the timing of these sales was planned rather than a discretionary, spur-of-the-moment decision.

How many total shares did the Rapport Therapeutics (RAPP) CDO sell in this Form 4?

Across the three reported transactions, Chief Development Officer Yeleswaram Krishnaswamy sold a total of 19,865 shares of Rapport Therapeutics common stock. The individual trades were 500 shares on April 10, 9,165 shares on April 13, and 10,200 shares on April 14, 2026, all in open-market sales.

Does this Rapport Therapeutics (RAPP) Form 4 show any derivative or option exercises?

No derivative or option exercises are reported in this Form 4. All three transactions involve non-derivative common stock sales only. The derivative section of the filing shows no derivative transactions, so the disclosure here focuses solely on common stock held and sold directly.